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Background. In the last few years there has been an increas-
ing interest in exploring the human proteome. In particular,
efforts have focused on developing strategies to generate re-
producible protein maps of normal cells, tissues, and biologic
fluids, from which studies can then compare protein expression
between different groups (e.g., healthy individuals vs. those with
a specific pathologic state).
Methods. Various extrinsic factors (instrument settings, ma-
trix composition, urine storage post void, freeze-thaw cy-
cles) and intrinsic factors (blood in urine, urine dilution,
first-void vs. midstream urine) were analyzed with respect to
their impact on urine protein profiling using surface-enhanced
laser-desorption/ionization time-of-flight mass spectrometry
(SELDI-TOF-MS).
Results. Extrinsic factors that critically influenced repro-
ducibility and peak detection of urine protein profiling were
matrix composition and instrument settings, while freeze-thaw
cycles had minimal impact. Midstream urines samples did not
undergo changes in their protein profile when stored for three
days at 4◦C. Intrinsic factors that influenced normal urine pro-
tein profiling were blood in the urine and urine dilution. Female
first-void urine had a significantly different ratio of proteins
present compared to a midstream urine sample. Limitations of
the SELDI-TOF-MS technique included ion suppression and
quantification of individual proteins when protein composition
was complex.
Conclusion. SELDI-TOF-MS offers a unique platform for
high throughput urine protein profiling; however, standardiza-
tion of analysis conditions is critical, and both extrinsic and
intrinsic factors must be taken into account for accurate data
interpretation.
In the last few years there has been an increasing inter-
est in exploring the proteome of human urine. A catalog
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of these proteins cannot only improve our knowledge of
kidney physiology [1], but can also allow the identifica-
tion of novel proteins associated with pathologic states.
Indeed, it may be possible to identify potential biomark-
ers to diagnose and/or monitor renal disease [2–4].
At present, there are several techniques to identify and
compare the expression of proteins, each with advantages
and disadvantages. The most established method is pro-
tein separation by two-dimensional gel electrophoresis
(2-DE) followed by in-gel digestion and peptide mass
fingerprinting by mass spectrometry. This method allows
for the comparison of the relative abundance of proteins.
In recent literature, Thongboonkerd et al [5] identified 67
protein forms of 47 unique proteins in normal urine by
2-DE. However, there are several limitations of 2-DE as
a separation method for proteomic studies. The resolv-
able range of molecular weights is limited at both ends,
with a bias toward high-abundance proteins. In addition,
the technique requires relatively large amount of sam-
ple, is labor-intensive, and good gel-to-gel reproducibil-
ity can be hard to achieve [2, 6]. Thus, this approach is
not optimal for high throughput profiling. An alterna-
tive approach uses liquid chromatography as the separa-
tion step upstream from the mass spectrometer (LC-MS).
Using this approach, Spahr et al [7] identified 124 gene
products (proteins and translations of expressed se-
quence tags) in normal urine samples. While this tech-
nique provides information about the protein content
of the samples, little information about their relative
abundance can be obtained unless the proteins/peptides
are labeled first by isotope-coded affinity tags [8, 9]
or other protein/peptide labeling techniques. Further-
more, this method is still labor-intensive and has limited
throughput.
Surface-enhanced laser-desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF-MS) addresses
some of the limitations of both 2-DE and LC-MS.
It combines matrix-assisted laser-desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF-MS) to
surface chromatography. Specifically, a sample is applied
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to a chip surface carrying a functional group. After in-
cubation, proteins that do not bind to the surface are
removed by a simple wash step, and bound proteins are
analyzed by mass spectrometry. This approach, in con-
trast to the others described, allows for high throughput
profiling of multiple clinical samples. In this article, tech-
nical issues, pitfalls, and limitations of this technique in
protein profiling normal urine samples are described and
discussed.
METHODS
Urine collection and storage
Second-morning urine from healthy men and women
were collected in two different containers. The first 10–
20 mL of urine was considered as first-void urine, the
following 50–80 mL as midstream urine. Unless otherwise
stated, urine was centrifuged in a fixed-angle centrifuge
for 10 minutes at 2000 rpm (900g), the supernatant was
transferred into 2 mL cryo-tubes (Gordon Technologies,
Inc., Missisauga, Ontario, Canada), and stored at –70◦C.
All samples were obtained with informed consent and
ethics approval of the University of Manitoba IRB.
Urine sediments
Ten mL of freshly collected urine was centrifuged for
10 minutes at 2000 rpm. The pellet was analyzed with a
phase-contrast microscope at 400× augmentation and is
reported as cells per high-power field (hpf).
Protein chip preparation and reading
Normal phase chips (ProteinChip NP20; Ciphergen,
Freemont, CA, USA), which bind proteins through
hydrophilic and charged residues (including serine,
threonine, and lysine), were used for the analysis. Urine
samples were thawed on ice, shortly vortexed, and cen-
trifuged for 5 minutes at 10,000 rpm (to remove remaining
cell particles). Five lL of urine supernatant were applied
in duplicate to the chip and incubated for 20 minutes
in a humidity chamber. Spots were then washed three
times with 5 lL high-performance liquid chromatogra-
phy (HPLC)-grade water and air-dried for 10 minutes.
Saturated a-cyano-4-hydroxycinnamic acid (CHCA; Ci-
phergen) and sinapinic acid (SPA; Ciphergen) were
prepared in 50% acetonitrile/0.5% trifluoroacetic acid
according to the manufacturer’s instructions. Dilutions
of 20%, 35%, and 50% were used. One lL of matrix
solution (35% CHCA, unless otherwise specified) was
applied to each spot and air-dried. Unless stated other-
wise, chips were read with the following SELDI-TOF-MS
instrument (ProteinChip Reader II; Ciphergen) settings:
Laser intensity 230; detector sensitivity 6; detector volt-
age 1700 V; positions 15 to 85 were read with an incre-
ment of 5 (resulting in 15 different sampling positions);
16 laser shots were collected on each position (total shots
collected and averaged: 240/sample); eight warming shots
were fired at each position, which were not included in
the collection; the acquired mass range was from a mass-
over-charge (m/z) ratio of 0 to 80,000; lag time focus of
900 ns. Calibration was done externally with a mixture
of 4 proteins with masses ranging from 2 to 16 kD. Af-
ter baseline subtraction and normalization, peak labeling
was performed with the ProteinChip Software (version
3.1) for peaks with a signal-to-noise (S/N) ratio of ≥3 in
the m/z range from 2000–25,000.
RESULTS
Evaluation of reproducibility
It is critical to evaluate the reproducibility of urine pro-
tein profiling using the SELDI-TOF-MS approach before
establishing whether the urine protein profiles differ in
various clinical states. Reproducibility was evaluated by
applying one urine sample to 14 spots and reading the
spots using the protocol described above. The total num-
ber of detected peaks with an S/N-ratio ≥3 was 25 peaks/
spectrum (range, 23–29). Fourteen peaks common to all
spectra were selected and compared with regard to their
peak intensity by calculating the coefficient of variation.
They ranged from 8% to 30%, with the lowest vari-
ation seen in the high intensity peaks and the higher
variation seen in lower intensity peaks (Fig. 1A). This
is expected, as small differences in low intensity peaks
(e.g., 1.0 vs. 0.5) have a large influence on the calculated
coefficient of variation. Independent of the software as-
signment of protein peaks, it is important to conduct
manual inspection of the spectra, to determine whether
a specific peak is present. Low intensity peaks with
an S/N-ratio near the selected detection threshold (i.e.,
≥3) can be unlabelled and undetected by the software
(Fig. 1B).
Impact of extrinsic factors on reproducibility and peak
detection of urine protein profiles
The impact of matrix on the urine protein profile was
determined by comparing different dilutions of CHCA
and SPA (20%, 35%, 50%, and 100%) with the oth-
erwise unchanged protocol stated above. In the range
from 2–25 kD, 22, 26, 19, and 16 peaks were detected
using 20%, 35%, 50%, and 100% CHCA, respectively.
In contrast, 13, 19, 11, and 10 peaks were detected using
20%, 35%, 50%, and 100% SPA. Peak intensity below
8–10 kD was higher with CHCA, whereas SPA yielded
higher peak intensities above 8–10 kD (urine protein pro-
files not shown).
The impact of spot sampling protocols was determined
by comparing three different spot sampling protocols
with respect to peak detection in undiluted and diluted
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Fig. 1. Reproducibility of urine protein pro-
files. One urine sample was applied to 14 spots
and analyzed. (A) Fourteen peaks common to
all spectra were selected and compared with
regard to their peak intensity by calculating
the coefficients of variation. They ranged from
8% to 30%, with the lowest variation seen in
the high-intensity peaks and the higher varia-
tion seen in lower intensity peaks. (B) Parts of
4 randomly selected spectra from the obtained
14. Manual inspection of the spectra showed
the presence of an unlabelled peak (circle in
insert), although the spectra look the same by
“eyeball.”
urine: protocol 1 (standard protocol; see above); protocol
2 (standard protocol modified to sample on only 5 differ-
ent positions for a total of 80 shots/sample); protocol 3
[standard protocol modified to use a higher detector sen-
sitivity (10 instead of 6)]. Protocol 1 detected 34 peaks
in undiluted urine, whereas protocols 2 and 3 detected
only 21 and 26 peaks, respectively. In diluted urine (urine
creatinine 3.75 mmol/L) the peak counts were 20, 11, and
13, respectively (urine protein profiles not shown).
If the SELDI-TOF-MS approach is to be used in the
assessment of clinical samples, it is important to as-
sess the stability of the urine proteins before analysis.

































Fig. 2. Impact of storage on urine protein
profiles. (A) Representative female first-void
urine showing the appearance of new peaks
(+) in the 2–6kD range after storage for 3 days
at room temperature or at 4◦C. (B) Represen-
tative male midstream urine protein profile,
which showed only minor changes, whether it
was analyzed 2 hours after collection or after
storage for 3 days at room temperature or at
4◦C, respectively.
First-void and midstream urine samples from three fe-
males and three males were analyzed within 2 hours from
the time of collection, after storage for three days at room
temperature, and after three days at 4◦C. In all six sam-
ples, only minor differences in the midstream urine pro-
tein profiles could be detected after storage for three days
at 4◦C. However, in three first-void urines (two female,
one male), storage for three days at room temperature or
at 4◦C changed the spectra considerably. A series of new
peaks in the low-molecular weight range were detected
(Fig. 2). Storage of the urine samples at −70◦C did not
change the spectra compared with those obtained before
freezing. Furthermore, almost the same spectra could be
generated after four freeze-thaw cycles; however, a loss
of peaks was observed after the fifth freeze-thaw cycle
(Fig. 3).
































Fig. 3. Impact of freeze-thaw cycles on
urine protein profiles. Urine protein profiles
obtained before freeze and after 1 to 4
freeze-thaw cycles were unchanged, but an in-
creasing loss of intensity in some peaks was
detected (↓). After the fifth freeze-thaw cycle
some weak intensity peaks were not detected
(−).
Impact of intrinsic factors on normal urine
protein profiling
A potential confounding variable in the clinical set-
ting is if a urine sample is first-void or midstream. In all
three urine samples from males, there were almost no
differences between the protein profile of first-void and
midstream urine (Fig. 4A). However, in all three urine
samples from females, there are prominent peaks be-
tween 3.3 and 3.5 kD in the first-void urine fraction. These
peaks are greatly diminished in the midstream urine
sample, together with other changes in peak intensities
(Fig. 4B). Three of these peaks with average masses of
3370.3, 3441.2, and 3484.3 d are consistent with the masses
of the a-defensins 2, 1, and 3, respectively.
Another confounding variable in urine proteomic anal-
ysis is the presence of blood in urine. It can be present in
urine under normal conditions (e.g., menstruation) or in
association with urogenital tract pathologies. To investi-
gate the impact of blood on the normal urine profile, we
spiked 500 lL urine with 10 lL blood, which resulted in
a red coloring of the sample [sediment analysis showed
>100 red blood cells (RBC)/hpf]. In the subsequent anal-
ysis by SELDI-TOF-MS, four major peaks were detected
(Fig. 5B), which are consistent with the masses of the
hemoglobin a- and b-chains and their doubly charged
ions. Based on the virtual disappearance of these peaks af-
ter sample centrifugation before SELDI-TOF-MS anal-
ysis, it is likely that these peaks represent hemoglobin.
They were easily detectable as the most intense peaks up
to a 1:128 dilution of this sample, corresponding to 10 lL
blood in 64 mL diluted urine (urine protein profiles not
shown). However, even when the RBC were removed
by centrifugation, the urine was still contaminated with
serum proteins. This is suggested by the presence of peaks
with masses consistent with albumin in the urine protein
profile (Fig. 5C).
A dilute urine sample may limit the ability to detect the
normal urine protein profile. To address the issue of urine
concentration, urine was sampled from a healthy male
with a body weight of 75 kg after 20 hours of no fluid in-
take. The measured urine creatinine was 15 mmol/L and
the total protein was 0.11 g/L. At another time point,
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Fig. 4. Comparison between first-void and
midstream urine protein profiles (gel-view).
First-void and midstream urine protein pro-
files obtained from three females and three
males. In males, both urine samples had simi-
lar protein profiles, whereas in females there
are significant differences. The most promi-
nent difference in female first-void urine are
three peaks at 3370.3, 3441.2, and 3484.3 d
(↓), which are consistent with the masses
of the a-defensins 2, 1, and 3, respectively
(Swiss-Prot P59665+P59666; 3371.9, 3442.5,
3486.5 d). The calculated mass accuracy of the
surface-enhanced laser-desorption/ionization
time-of-flight mass spectrometry (SELDI-
TOF-MS) in this example is < 0.07%, which
is within the limits given by the manufacturer
(<0.1%).
the same individual was challenged with 4 L of fluid
over 2 hours, leading to dilute urine with a creatinine of
0.9 mmol/L and a total protein of 0.03 g/L. While the con-
centrated urine showed the normal peak profile (Fig. 6A),
the dilute urine sample showed only three peaks in the
range from 2–25 kD (Fig. 6E). To determine the detec-
tion threshold of the normal urine profile, the concen-
trated urine sample was serially diluted. At a 1:2 dilution,
which corresponds to a urine output of 2 L/day [calcu-
lated in our test person by: creatinine production/day
(0.2 mmol/kg/day × 75 kg) divided by urine creatinine
(7.5 mmol/L) = 2 L/day] the profile remained unchanged
(Fig. 6B). A progressive loss of urine profile peaks started
with a 1:4 dilution. The 1:16 dilution showed a spectrum
similar to the urine profile obtained after the fluid chal-
lenge (Fig. 6E).
Protein quantification with SELDI-TOF-MS
To determine if either the spectral peak intensity or
area provides a means for reliable protein quantification,
serial dilution of a single protein (ubiquitin, 8565 d) was
performed. There was an excellent correlation between
the amount of protein in the sample and peak intensity
(r2 = 0.95) or the area under the peak (r2 = 0.98) in non-
normalized spectra (Fig. 7A). Even in a mixture contain-
ing four other proteins, the correlation was maintained
(r2 = 0.99 for peak intensity and for the area under the
peak), but the peak intensities were 10 times lower with
the same amount of ubiquitin (Fig. 7B). When a com-
plex protein mixture (i.e., normal urine with a protein
concentration of 110 mg/L) was spiked with 1.0, 0.1, and
0.01 pmol/lL ubiquitin, only the first two concentrations
of ubiquitin were detectable (Fig. 7C). The peak intensity
dropped from 0.32 (1.0 pmol/lL) to 0.09 (0.1 pmol/lL),
which is only a 3.5 times decrease instead of the expected
10 times. Because only two measurements of peak inten-
sity were obtainable, no correlation was calculated.
DISCUSSION
In order to use SELDI-TOF-MS as a high throughput
urine protein profiling methodology, it is critical to define
those factors that affect reproducibility, as well as iden-
tify the confounding variables that affect the detection of
proteins that are known to be present in the sample.
Extrinsic factors
The most important extrinsic factors that influence re-
producibility and peak detection are the matrix com-
position and the instrument settings. Matrix allows for
efficient ionization and vaporization of proteins [10].
The most popular matrices for the SELDI-TOF-MS
































Fig. 5. Impact of blood in urine on urine
protein profiles. (A) Protein profile of urine
sample from a healthy male. (B) Protein
profile after spiking the same sample from
(A) with blood (10 lL blood in 500 lL
urine). Four peaks appear which are con-
sistent with the masses of singly and dou-
bly charged hemoglobin a- and b-chains
(Swiss-Prot P01922: 15126 d; P02023: 15867
d). The calculated mass accuracy of the
surface-enhanced laser-desorption/ionization
time-of-flight mass spectrometry (SELDI-
TOF-MS) in this example is <0.13%, which
is slightly above the limits given by the man-
ufacturer (<0.1%). (C) Protein profile af-
ter centrifugation of the same blood-spiked
urine sample from (B). Only trace amounts
of two of these peaks were detectable (∗);
however, contamination with serum pro-
teins was obvious (e.g., peaks consistent with
masses of serum albumin were detected).
Albumin has a molecular weight of 66472
d with its multiply charged ions at an m/z
of 33236 (double-charged), 22157 (triple-
charged), 16618 (quadruple-charged), 13294
(quintuple-charged), and 11079 (sextuple-
charged).
system are SPA and CHCA. Saturated SPA is preferable
for looking at masses above 10–20 kD, while 10%–20%
CHCA provides the best resolution for proteins/peptides
up to about 5 kD. For urine protein profiling from 2–
25 kD, more peaks and a higher degree of resolution were
observed with 35% CHCA. Instrument settings such as
detector sensitivity, detector voltage, and laser intensity
have to be determined individually. The higher the de-
tector sensitivity and voltage or the laser intensity, the
better the detection of high-mass proteins. This is accom-
panied by an increase in background noise, which limits
detection of low intensity peaks.
The number of positions sampled on a spot is an im-
portant parameter for optimal peak detection. Ideally, all
proteins are distributed homogeneously on the spot and
are crystallized homogeneously in the matrix. If so, one
would expect to generate the same spectra at every posi-
tion. From the three spot sampling protocols it is clear that
there are “hot positions,” where proteins are clustered on
the spot leading to the detection of an abundance of peaks
with a high intensity. Similarly, there are “cold positions,”
where only few or even no peaks are detected. Unfortu-
nately, “hot position” sampling may not accurately pro-
file low abundant proteins due to ion suppression that
can occur due to high abundant proteins. Therefore, the
most representative spectra for a given urine sample is
achieved by sampling many different spot positions and
combining the data. This is especially true for dilute urine
samples.
The stability of urine proteins under various storage
conditions is important to know. Recent studies have
found no or just small changes in albumin-, retinol-
binding protein-, N-acetyl glucosaminidase-, IgG- and
kappa/lambda light-chain concentrations after storage at
room temperature, 4◦C, −20◦C, and −70◦C [11–14]. Our
experiments using SELDI-TOF-MS found that up to four
freeze-thaw cycles at −70◦C did not alter the urine pro-
tein profile significantly; thereafter, peak intensities be-
came weaker. The protein profiles of all midstream urine
samples remained almost unchanged after storage for
three days at 4◦C, whereas three of six first-void urines
underwent major changes. First-void urine can have sig-
nificant bacterial contamination, resulting in either urine
protein degradation and/or contamination with bacterial
proteins within a few days.
Intrinsic factors
Midstream urine is the standard for almost all urine
analysis. In a clinical setting, there are always urine sam-
ples that are not midstream urines. Therefore, knowing









































1:2 dilution of A
1:4 dilution of A
1:8 dilution of A
1:16 dilution of A
Fig. 6. Impact of dilution on urine protein
profiles. Protein profile obtained from (A)
Urine collected after a 20-hour period of no
fluid intake. (B-E) Serial dilution of urine
sample (A). (F) Urine collected after a 4-L
fluid challenge. Starting with a 1:4 dilution, a
continuous loss of peaks was observed.
the variation in urine protein profiles that may occur be-
tween first-void and midstream urines is important. There
were no clear differences between first-void and mid-
stream urine in males, whereas in females, variations were
easily detectable. For example, a peak cluster between 3.3
and 3.5 kD (consistent with the masses of the a-defensins)
is present in female first-void urine in high intensity. This
peak cluster is either absent or of low intensity in female
midstream urine samples. Indeed, a-defensins, which are
an important part of the human antimicrobial defense [15,
16], have been detected by SELDI-TOF-MS technology
in urine [3], as well as in culture supernatants of human







































































Fig. 7. Impact of protein concentration on
peak intensity. (A) Dilution series of a single
protein (ubiquitin, 8565 d) from 10 pmol/lL
to 0.01 pmol/lL (equals 85.6, 8.56, 0.85, and
0.08 ng/lL, respectively). (B) Dilution series
of ubiquitin from 1 pmol/lL to 0.01 pmol/lL
in a mixture of four other proteins with con-
stant concentrations (1.5 pmol/lL dynorphin
A, 1 pmol/lL insulin, 0.3 pmol/lL cytochrome
C and 0.3 pmol/lL superoxide dismutase). (C)
Dilution series of ubiquitin from 1 pmol/lL to
0.01 pmol/lL spiked into normal male urine
with a protein concentration of 110 mg/L.
CD8+ T-cells [17]. The differences in the protein pro-
file between first-void and midstream urines may be ex-
plained by urethral secretion of these proteins, which are
then washed away by the first-void urine. Therefore, con-
sistent urine protein profiling requires midstream urine
samples for analysis, because first-void urine has a dif-
ferent protein composition than midstream urine and is
more prone to protein degradation.
Blood was observed to be a major confounding variable
affecting the normal urine protein profile. Not only did
new peaks appear (i.e., peaks consistent with the masses
of hemoglobin and albumin), but many of the normal
peaks observed became undetectable. This is likely due
to ion suppression by the blood proteins. Notably, even
with a dilution of 10 lL blood in 64 mL diluted urine
(1:6400 dilution), the peaks consistent with hemoglobin
remained dominant. Clearly, such contamination invali-
dates any interpretation of the urine protein profile. Al-
though centrifugation of the urine sample removes RBC,
contamination with serum proteins will still continue to
confound the urine protein profile.
Depending on fluid intake, the kidneys can concen-
trate urine to an output as low as 0.5 L/day, or di-
lute urine to almost 20 L/day. Under normal conditions,
about 1–2 L urine are excreted per day. In a very di-
lute urine sample (urine creatinine 0.9 mmol/L), most
of the proteins could not be detected on an NP20-chip.
The threshold for a stable urine protein profile on an
NP20-chip was a urine output of 2 L/day. Because every
ProteinChip type has different binding capacities, the de-
tection threshold has to be determined for every chip type
individually.
In healthy individuals and under normal conditions,
urine dilution, contamination with blood, and the por-
tion of the urine specimen (first-void versus midstream)
are the most obvious intrinsic factors that influence repro-
ducibility and detection of proteins in profiles acquired
by SELDI-TOF-MS. In addition, several transient “be-
nign” states (e.g., fever, exercise) are known to increase
the amount of proteins in urine [18, 19] by changing
the size/charge selectivity of the glomerular barrier or
by changing protein reabsorption/degradation through
tubular cells [20, 21]. Whether different proteins appear
in urine during these conditions has not yet been deter-
mined. However, these transient “benign” factors will
need to be taken into account when comparing urine pro-
tein profiles from individuals in which such processes may
be observed.
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Protein quantification
Peak height and area under the peak have been used to
reflect protein abundance [3, 22]. Although good corre-
lation between the amount of a single protein alone or in
a mixture with four other proteins and the peak intensity
was found, it is questionable whether this remains true in
a complex protein mixture (e.g., urine) due to many influ-
encing factors like ion suppression and competition for
binding sites on the ProteinChips. Therefore, care should
be taken in comparing relative peak heights between two
different urine protein profiles as an indicator of change
in protein abundance under different circumstances (e.g.,
normal vs. pathologic state).
CONCLUSION
SELDI-TOF-MS offers many advantages for protein
profiling in urine. First, only 5 to 10 lL of sample is needed
for one analysis. Second, due to the simple chip prepara-
tion, many samples can be analyzed quickly. Third, the
washing step removes most of the salts, which otherwise
interfere with mass spectrometric analysis. And fourth,
the impact of different chromatographic chemistries can
be analyzed, which may allow one to find optimal purifi-
cation conditions for a protein of interest in a short time
with small amounts of sample. However, standardization
of analysis conditions is essential, and both extrinsic and
intrinsic factors must be taken into account for accurate
data interpretation.
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